Zura Bio Limited is a clinical-stage biotechnology company developing biologic medicines targeting immune and inflammatory disorders. The company's pipeline consists of three monoclonal antibodies and antibody-based therapeutics in various stages of clinical development. Tibulizumab, its lead program, is a bispecific dual-antagonist antibody currently in Phase 2 trials that targets interleukin-17A and B-cell activating factor. The company is also developing Torudokimab (ZB-880), a monoclonal antibody targeting IL-33 that has completed Phase 1/2 studies, and Crebankitug (ZB-168), which neutralizes the IL-7 receptor alpha chain and has completed Phase 1/1b trials.
As a clinical-stage entity, Zura Bio has not generated product revenues to date. The company operates with a focused team of approximately 30 full-time employees and is headquartered in Henderson, Nevada. Zura Bio was incorporated in the Cayman Islands and is listed on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.60 | $-0.60 | +71.3% | |
| 2023 | $-2.09 | $-2.09 | — | |
| 2022 | — | — | — | |
| 2021 | — | — | — |